It has implications for treatment decisions and prognosis.
In a phase 2 trial, 72% of patients with high-grade clinical nonmuscle-invasive bladder cancer had a complete response at 3 months.
Researchers found elevated familial risks for testicular, prostate, bladder, and kidney cancers.
Risk factors include male gender, distant disease, increasing age, race/ethnicity
In a Canadian study, long wait times before a first urologist visit was associated with a 29% higher risk of death after radical cystectomy.
Smoking pot decreased the likelihood of the malignancy by 45%, whereas smoking tobacco only increased the likelihood by 52%.
Patients aged 70 and older are less likely than younger patients to receive post-cystectomy treatment, despite survival benefit
In community practice, overall rate of compliance with AUA Best Practices is less than 60 percent
Study of patients with muscle-invasive bladder cancer documents a particularly large increase in the use of neoadjuvant chemotherapy.
In a small randomized trial, functional and oncologic results did not differ significantly between the 2 approaches
These include patients with positive lymph nodes and surgical margins after cystectomy.
Transurethral resection of bladder tumor can cause cancer cells to be infused into the bloodstream.
Recurrence-free survival was 66 percent at five years for patients with bladder cancer who had laparoscopic radical cystectomy.
NBI visualized non-muscle-invasive bladder cancer lesions in 17% more patients and 24% more tumors than white light.
High serum levels of vitamin D may have a protective effect against bladder cancer.
Active smokers more knowledgeable than former, never smokers; often cite urologist as source of info.
A 15-feature 'genomic classifier' surpassed the prognostic potential of standard clinical variables for bladder cancer risk.
Absence of muscle tissue in bladder cancer biopsy samples is common and associated with increased risk of death.
Johns Hopkins University in Baltimore on October 15 will launch the world's first institute devoted to bladder cancer.
Investigators report earlier bladder tumor relapse and higher risk of T-stage progression.
Keytruda (pembrolizumab) shows promising results for the treatment of PD-L1 positive bladder cancer.
In adjusted analyses, female transplant recipients had a significantly increased risk of urologic cancer and men did not.
It is associated with a 20-fold increased likelihood of the malignancy, British study shows.
Studies show integrated program effective for depression in patients with cancer.
Studies have suggested a strong "placebo effect" in the treatment of interstitial cystitis/bladder pain syndrome.
As body mass index increases, so does the risk of kidney and bladder cancers in men and stomach, ovarian, and colon cancers in women.
Study reveals a 2-fold greater likelihood of primary kidney and bladder cancer compared with men in the general population.
Current smoking and smoking cessation prior to diagnosis does not alter risk of recurrence or progression of non-muscle-invasive bladder cancer.
Study shows a significantly better 5-year cancer-specific survival rate compared with radical cystectomy.
Use of the drug reduced the risk of recurrence and cancer-related mortality in diabetic patients undergoing radical cystectomy.
- Prostate Cancer Active Surveillance Outcomes Vary by Disease Risk
- High BMI a Plus for Some Metastatic Kidney Cancer Patients
- Statins May Prolong Life in Patients with Advanced Kidney Cancer
- Adjuvant Kidney Cancer Drugs Fail to Improve Outcomes
- Statins Plus ADT After Prostate Cancer Radiotherapy Ups Survival
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)